Tag Archives: CTLA4

Loss of NFE2L3 Protects against Inflammation-Induced Colorectal Cancer through Modulation of the Tumor Microenvironment

Researchers investigated the role of the NFE2L3 transcription factor in inflammation-induced colorectal cancer.
[Oncogene]
[zotpress userid=” items=’SPXSDFJC’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Role of CTLA Inhibition in Management of Non-Small Cell Lung Cancer

The authors review the current role for CTLA-4 inhibitors in early-stage resectable NSCLC, unresectable stage III NSCLC, and in metastatic NSCLC.
[Current Oncology Reports]
[zotpress userid=” items=’SPXSDFJC’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Blockade of Beta-Adrenergic Receptors Reduces Cancer Growth and Enhances the Response to Anti-CTLA4 Therapy by Modulating the Tumor Microenvironment

Investigators showed that oral administration of propranolol delayed tumor progression of MCA205 fibrosarcoma model and MC38 colon cancer model and increased the survival rate of tumor bearing mice.
[Oncogene]
[zotpress userid=’7992332′ items=’BBBBBBBB’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

CD29 Targeted Near-Infrared Photoimmunotherapy (NIR-PIT) in the Treatment of a Pigmented Melanoma Model

The authors investigated the efficacy of CD29- and CD44-targeted NIR-PIT (CD29-PIT and CD44-PIT, respectively) in the B16 melanoma model, which was highly pigmented.
[Oncoimmunology]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

TGFβ2 Induces the Soluble Isoform of CTLA-4 – Implications for CTLA-4 Based Checkpoint Inhibitor Antibodies in Malignant Melanoma

Scientists examined the effect of selectively blocking the function of sCTLA-4 on in vitro immune responses from volunteer healthy or melanoma patient PBMC samples.
[Frontiers in Immunology]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

CD4+ T-cell Activation of Bone Marrow Causes Bone Fragility and Insulin Resistance in Type 2 Diabetes

In type 2 diabetes mellitus mice scientists inhibited systemic activation of T cells with a fusion protein between the extracellular domain of Cytotoxic T-Lymphocyte Antigen 4 and the Fc domain of human immunoglobulin G.
[Bone]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
AbstractGraphical Abstract
Bookmark

No account yet? Register

Share

Natural Killer Cells and Immune-Checkpoint Inhibitor Therapy: Current Knowledge and New Challenges

Scientists overview and discuss this new perspective, focusing on the most relevant candidates for this role among the variety of potential NK immune checkpoints.
[Molecular Therapy-Oncolytics]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
AbstractFull ArticleGraphical Abstract
Bookmark

No account yet? Register

Share

Purple Biotech Expands Research Collaboration in Immuno-Oncology in Combination with NT219

Purple Biotech Ltd. announced the expansion of an existing research agreement, led by Dr. Menashe Bar-Eli at The University of Texas MD Anderson Cancer Center, and will evaluate the potential efficacy of the combination of NT219, a dual inhibitor, novel small molecule that simultaneously targets IRS1/2 and STAT3, and immuno-oncology drugs, such as anti-CTLA4 or anti-PD1/PDL1 antibodies.
[Purple Biotech Ltd. (GlobeNewswire, Inc.)]
[zotpress userid=” items=’DDDDDDDD’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Nanobody-Based CTLA4 Inhibitors for Immune Checkpoint Blockade Therapy of Canine Cancer Patients

The authors developed, characterized and assessed whether chimeric heavy chain only antibodies against CTLA4 were viable therapeutic candidates for the treatment of canine cancers.
[Scientific Reports]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Enhancing Immunotherapy in Cancer by Targeting Emerging Immunomodulatory Pathways

Scientists discuss the translational potential and clinical development of agents targeting both co-stimulatory and co-inhibitory T cell receptors.
[Nature Reviews Clinical Oncology]
[zotpress userid=’6445218′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

A Small-Molecule SUMOylation Inhibitor Activates Antitumor Immune Responses and Potentiates Immune Therapies in Preclinical Models

Ex vivo treatment of mouse and human dendritic cells promoted their IFN1-dependent activation, and vaccination studies in mice demonstrated stimulation of antigen cross-presentation and T cell priming in vivo.
[Science Translational Medicine]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share
Share